ATI RN
ATI Proctored Pharmacology 2023
1. A healthcare professional is preparing to administer IV Dantrolene to a client who has developed Malignant Hyperthermia during surgery. Which of the following actions should the healthcare professional take?
- A. Dilute the medication with sterile water and administer it rapidly.
- B. Store the medication in a refrigerator until use.
- C. Administer the medication through a large-bore IV catheter.
- D. Administer the medication via an infusion pump over 60 minutes.
Correct answer: C
Rationale: Dantrolene should be administered through a large-bore IV catheter because it is highly irritating to tissues and can cause vein irritation or thrombophlebitis if administered through a small vein. Using a large-bore IV catheter helps to minimize the risk of tissue damage and ensures proper and safe administration of the medication in emergency situations like Malignant Hyperthermia. Choices A, B, and D are incorrect because diluting the medication with sterile water and administering it rapidly can lead to tissue damage, storing the medication in a refrigerator is not necessary, and administering the medication via an infusion pump over 60 minutes is not appropriate in emergency situations like Malignant Hyperthermia where rapid administration is crucial.
2. A client is receiving daily doses of Oprelvekin. Which of the following laboratory values should be monitored to determine the effectiveness of this medication?
- A. Hemoglobin
- B. Absolute neutrophil count
- C. Platelet count
- D. Total white blood cell count
Correct answer: C
Rationale: Oprelvekin is a medication that stimulates platelet production. Therefore, monitoring the platelet count is essential to assess the effectiveness of this drug. The expected outcome for oprelvekin therapy is a platelet count greater than 50,000/mm^3. Changes in platelet count can indicate the response to the medication and help in adjusting the treatment plan accordingly. Monitoring hemoglobin, absolute neutrophil count, or total white blood cell count is not directly related to the mechanism of action of Oprelvekin and therefore would not provide accurate information on the drug's effectiveness.
3. A client is prescribed Digoxin. Which of the following findings should the nurse monitor as a sign of potential toxicity?
- A. Bradycardia
- B. Hypertension
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Bradycardia is a common sign of Digoxin toxicity. Digoxin can lead to toxicity, which can manifest as various signs and symptoms, including bradycardia. Monitoring the client's heart rate closely is crucial to detect and manage potential toxicity early. Hypertension, hyperglycemia, and hypocalcemia are not typically associated with Digoxin toxicity; therefore, they are incorrect choices.
4. When caring for a client prescribed Digoxin, which of the following laboratory values should the nurse monitor to assess for potential toxicity?
- A. Sodium
- B. Potassium
- C. Magnesium
- D. Calcium
Correct answer: B
Rationale: When a client is prescribed Digoxin, monitoring potassium levels is crucial as hypokalemia can increase the risk of Digoxin toxicity. Low potassium levels can potentiate the effects of Digoxin on the heart, leading to toxicity. Therefore, regular monitoring of potassium levels helps in preventing adverse effects and ensuring the safe use of Digoxin. Sodium, magnesium, and calcium levels are not directly associated with Digoxin toxicity; hence, they are not the primary focus for monitoring in this case.
5. A client is receiving treatment with methotrexate. Which of the following supplements should the nurse instruct the client to take?
- A. Folic acid
- B. Vitamin D
- C. Calcium
- D. Iron
Correct answer: A
Rationale: The nurse should instruct the client to take folic acid when receiving treatment with methotrexate to reduce the risk of methotrexate toxicity. Methotrexate acts as a folic acid antagonist, leading to folic acid deficiency, which can be counteracted by supplementing with folic acid. Vitamin D, calcium, and iron are not specifically recommended to counteract methotrexate effects and do not play a significant role in mitigating methotrexate toxicity.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access